Dr. Reddy’s Laboratories (NYSE:RDY) Releases Earnings Results, Beats Expectations By $0.02 EPS

Dr. Reddy’s Laboratories (NYSE:RDY) released its quarterly earnings data on Friday. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.02, Zacks reports. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The company had revenue of $996.17 million during the quarter, compared to analyst estimates of $83.70 billion.

Dr. Reddy’s Laboratories Stock Up 1.8 %

Shares of Dr. Reddy’s Laboratories stock opened at $13.42 on Friday. Dr. Reddy’s Laboratories has a 1 year low of $12.26 and a 1 year high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a market cap of $11.20 billion, a P/E ratio of 21.37 and a beta of 0.33. The stock has a 50-day moving average price of $13.29 and a 200 day moving average price of $14.07.

Analyst Ratings Changes

Separately, StockNews.com upgraded Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.